New approaches for patients with advanced radioiodine-refractory thyroid cancer

Table 3 Summary of the efficacy and safety of lenvatinib in patients with thyroid cancer reported by phase III clinical trial and real-life studies

Ref.	n	Patients with prior TKIs %	CR %	PR %	SD %	Median	Median	Most frequent AE	Most frequent grade 3-4 AE
						PFS (mo)	OS (mo)
Schlumberger et al[7] 2015	261	25	1	63	23	18.3	-	Hypertension, 68%	Hypertension, 42%
Berdelou et al[16], 2017	75	68	0	31	51	10	-	Fatigue, 75%	Hypertension 35%
Jasim et al[17], 2017	25	31	0	50	28	-	-	Hypertension 64%	Hypertension 40%
Sugino et al[18], 2018	29	13	0	69	21	-	-	Hypertension 76%	-
Locati et al[19], 2019	94	64	0	36	41	10.8	23.8	Fatigue, 13%	Fatigue, 8%
Lee et al[20], 2019	57	89	0	38	60	5.1	19.3	General weakness 43%
Masaki et al[21], 2019	42	10	0	62	24	13.8	-	Hypertension, 83%	Proteinuria, 36%
Aydemirli et al[22], 2020	39	77	2	33	37	9.7	18.3	Hypertension and fatigue, 64%	Hypertension, 28%
Jerkovich et al[23], 2020	22	59	4	32	32	13.7	-	Hypertension, 64%	Hypertension, 23%

TKIs: Tyrosine kinase inhibitors; CR: Complete response; PR: Partial response; SD: Stable disease; PFS: Progression free survival; OS: Overall survival; AE: Adverse event.